Conexeu Lists 25.27M Shares, Initiates B.R.E.A.S.T.™ Matrix Trials at Wake Forest
CNXU•Conexeu Sciences launched on Nasdaq May 21 with 25.27 million shares issued and initiated preclinical development of its B.R.E.A.S.T.™ 3D-printed breast matrix at Wake Forest Institute’s iTOPS platform to evaluate durability and integration. The company’s CXU™ matrix platform aims multiple markets and plans a predicate 510(k) submission in early 2027.
1. Nasdaq Listing and Share Structure
Conexeu Sciences began trading on Nasdaq on May 21 with 25,269,996 shares issued and 35,238,222 fully diluted following an exclusive advisory engagement with H.C. Wainwright & Co.
2. Preclinical Program at WFIRM
On May 27, Conexeu initiated a preclinical development program for its B.R.E.A.S.T.™ 3D-printed breast-reconstruction matrix at Wake Forest Institute’s Integrated Tissue-Organ Printing System to assess durability under physiological conditions, host-tissue integration and scaffold resorbability.
3. CXU™ Platform and Regulatory Path
The proprietary CXU™ extracellular-matrix technology holds issued patents in the US, EU, Japan and Australia, targets wound care, dental and body-contouring applications, and is pursuing a predicate-based 510(k) submission planned for early 2027.
